HEALTHCARE RESOURCE UTILISATION IN A REAL-WORLD EUROPEAN GENERALISED MYASTHENIA GRAVIS POPULATION: PHYSICIAN-REPORTED DATA FROM FIVE COUNTRIES
Author(s)
Tom Denee, MBA, PharmD1, Wisam Karmous, PharmD, MS2, Gregor Gibson, BSc3, Hannah Connolly, MChem3, Shiva Lauretta Birija, BSc3, Beth Poirrette, MSc3, Amy Foster, BSc4, Wim Noel, PhD5, Giorgio Maria Boggia, MD, MBA6.
1Johnson & Johnson, Breda, Netherlands, 2Johnson & Johnson, Issy les Moulineaux, France, 3Adelphi Real World, Bollington, United Kingdom, 4ADELPHI REAL WORLD, Bollington, United Kingdom, 5Johnson & Johnson, Beerse, Belgium, 6Johnson & Johnson, Milan, Italy.
1Johnson & Johnson, Breda, Netherlands, 2Johnson & Johnson, Issy les Moulineaux, France, 3Adelphi Real World, Bollington, United Kingdom, 4ADELPHI REAL WORLD, Bollington, United Kingdom, 5Johnson & Johnson, Beerse, Belgium, 6Johnson & Johnson, Milan, Italy.
OBJECTIVES: gMG is a rare autoantibody-mediated neuromuscular condition manifesting as muscle weakness and fatigue with unpredictable symptom exacerbations and myasthenic crises. An unmet need to address the high healthcare resource utilization (HCRU) remains. This research aims to describe the HCRU of generalised Myasthenia Gravis (gMG) patients in five European countries.
METHODS: Data were drawn from the Adelphi gMG Disease Specific Programme™, a cross-sectional dataset of neurologists reporting on their consulting gMG patients between January-November 2025 in Germany, Italy, France, Spain and the UK. Descriptive data on demographics, clinical characteristics, HCRU, current treatments available, at the time of survey, are presented.
RESULTS: Ninety-seven physicians reported on 605 patients, 51.9% were female and 81.9% were acetylcholine receptor autoantibody positive. Mean (standard deviation; SD) patient age was 52.9 (15.3) years and diagnosis of gMG had occurred 4.0 (4.9) years prior. Mean (SD) Myasthenia Gravis - Activities of Daily Living score was 4.6 (3.3) and 57.0% were in Myasthenia Gravis Foundation of America class II (mild). Overall, 91.7% were prescribed treatment at the time of survey. Among patients prescribed treatment, 15.9% were prescribed neonatal fragment crystallizable receptor inhibitors (FcRn) and 13.7% were prescribed novel complement inhibitors (C5I). Overall, since their diagnosis of gMG, 35.4% had experienced ≥1 symptom exacerbation and 19.3% had experienced ≥1 myasthenic crisis (non-exclusive). Of those, 30.3% and 40.7% respectively, had experienced ≥1 in the 12 months prior to survey. Across all healthcare practitioners, patients had a mean (SD) 5.2 (4.2) outpatient consultations in the 12 months prior to survey and 18.5% had been hospitalised at least once with 74.8% of recent hospitalisations involving admittance through the emergency room and 86.9% involving an overnight stay.
CONCLUSIONS: gMG patients continued to experience significant clinical events and emergency hospitalisations. An unmet need remains to reduce the risk of clinical events and the high HCRU due to gMG.
METHODS: Data were drawn from the Adelphi gMG Disease Specific Programme™, a cross-sectional dataset of neurologists reporting on their consulting gMG patients between January-November 2025 in Germany, Italy, France, Spain and the UK. Descriptive data on demographics, clinical characteristics, HCRU, current treatments available, at the time of survey, are presented.
RESULTS: Ninety-seven physicians reported on 605 patients, 51.9% were female and 81.9% were acetylcholine receptor autoantibody positive. Mean (standard deviation; SD) patient age was 52.9 (15.3) years and diagnosis of gMG had occurred 4.0 (4.9) years prior. Mean (SD) Myasthenia Gravis - Activities of Daily Living score was 4.6 (3.3) and 57.0% were in Myasthenia Gravis Foundation of America class II (mild). Overall, 91.7% were prescribed treatment at the time of survey. Among patients prescribed treatment, 15.9% were prescribed neonatal fragment crystallizable receptor inhibitors (FcRn) and 13.7% were prescribed novel complement inhibitors (C5I). Overall, since their diagnosis of gMG, 35.4% had experienced ≥1 symptom exacerbation and 19.3% had experienced ≥1 myasthenic crisis (non-exclusive). Of those, 30.3% and 40.7% respectively, had experienced ≥1 in the 12 months prior to survey. Across all healthcare practitioners, patients had a mean (SD) 5.2 (4.2) outpatient consultations in the 12 months prior to survey and 18.5% had been hospitalised at least once with 74.8% of recent hospitalisations involving admittance through the emergency room and 86.9% involving an overnight stay.
CONCLUSIONS: gMG patients continued to experience significant clinical events and emergency hospitalisations. An unmet need remains to reduce the risk of clinical events and the high HCRU due to gMG.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
RWD30
Topic
Clinical Outcomes, Real World Data & Information Systems
Disease
Neurological Disorders, Rare & Orphan Diseases